Theravance Biopharma (TBPH) Interest Coverage Ratio (2014 - 2026)
Theravance Biopharma's (TBPH) quarterly Interest Coverage Ratio came in at 148.17 in Q1 2026, down 560.07% year-on-year from 32.21 in Q1 2025, and down 7034.73% on a QoQ basis from 2.14 in Q4 2025.
Theravance Biopharma (TBPH) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Interest Coverage Ratio data on file, last reported at 148.17 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 560.07% year-over-year to 148.17 in Q1 2026; TTM through Mar 2026 was 21.08, a 207.54% increase from a year earlier, with the FY2025 full-year figure at 0.01, up 92.34% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 148.17, down from 2.14 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for TBPH reached as high as 2.14 in Q4 2025 and fell as low as 148.17 in Q1 2026.
- Historically, Interest Coverage Ratio has averaged 23.93 across 5 years, with a median of 15.79 in 2024.
- Across the five-year window, Interest Coverage Ratio slumped 1789.15% in 2024 and surged 114.93% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 5.92 in 2022, then jumped by 87.2% to 0.76 in 2023, then tumbled by 1789.15% to 14.31 in 2024, then surged by 114.93% to 2.14 in 2025, then plunged by 7034.73% to 148.17 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 148.17 in Q1 2026, 2.14 in Q4 2025, and 11.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | -148.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -148.17 |
| Dec 31, 2025 | 2.14 |
| Sep 30, 2025 | -11.27 |
| Jun 30, 2025 | -4.11 |
| Mar 31, 2025 | -22.45 |
| Dec 31, 2024 | -14.31 |
| Sep 30, 2024 | -17.20 |
| Jun 30, 2024 | -24.39 |
| Mar 31, 2024 | -17.82 |
| Dec 31, 2023 | -0.76 |
| Sep 30, 2023 | -14.38 |
| Jun 30, 2023 | -28.39 |
| Mar 31, 2023 | -45.29 |
| Sep 30, 2022 | -5.92 |
| Jun 30, 2022 | -12.58 |
| Mar 31, 2022 | -18.02 |
| Dec 31, 2021 | -26.28 |
| Sep 30, 2021 | -25.10 |
| Jun 30, 2021 | -5.52 |
| Mar 31, 2021 | -5.83 |